MARINOMED
Marinomed is a biopharmaceutical development company focusing on the development of innovative therapies based on patent protected technology platforms. Products against respiratory viruses derived from the proprietary MAVIREX platform are marketed with renowned partners in a growing number of countries around the globe. The new MARINOSOLV platform allows novel stable aqueous formulations of hardly soluble compounds such as corticosteroids, enabling a faster onset of action and a better bioavailability. The MARINOSOLV technology is not limited to a specific compound and has the potential to facilitate delivery of any compound with solubility issues. Marinomed was founded on 2006 and is headquartered in Vienna, Austria.
MARINOMED
Industry:
Biopharma Biotechnology Health Care Medical Product Design Therapeutics
Founded:
2006-01-01
Address:
Vienna, Wien, Austria
Country:
Austria
Website Url:
http://www.marinomed.com
Total Employee:
11+
Status:
Active
Contact:
+43 1 25077 4460
Email Addresses:
[email protected]
Total Funding:
1.56 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager Google Universal Analytics Global Site Tag Mobile Non Scaleable Content
Similar Organizations
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
U3 Pharma
U3 Pharma is a pharmaceutical company that focuses in targeted cancer drug development.
Current Advisors List
Current Employees Featured
Founder
Investors List
aws Mittelstandsfonds
aws Mittelstandsfonds investment in Private Equity Round - Marinomed
Arax Capital Partners
Arax Capital Partners investment in Venture Round - Marinomed
Arax Capital Partners
Arax Capital Partners investment in Seed Round - Marinomed
Arax Capital Partners
Arax Capital Partners investment in Venture Round - Marinomed
Official Site Inspections
http://www.marinomed.com Semrush global rank: 3.79 M Semrush visits lastest month: 3.52 K
- Host name: 45.144.187.21
- IP address: 45.144.187.21
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Marinomed"
Marinomed Biotech AG :: Marinomed
Marinomed has the vision to transform the lives of people suffering from diseases with limited or no treatment options in two key therapeutic areas: virology and immunology. Driven by …See details»
Strategy & Mission - Marinomed
Marinomed develops pharmaceutical products and medical devices in the therapeutic areas of virology and immunology. Marinomed's core competencies are preclinical and early research and development with the aim of generating …See details»
Marinomed - Crunchbase Company Profile & Funding
Marinomed is a biopharmaceutical development company focusing on the development of innovative therapies based on patent protected technology platforms. Products against respiratory viruses derived from the proprietary …See details»
Career - Marinomed
Marinomed is composed of a small team in which management and staff work closely together. Our open and family friendly environment also offers flexible working conditions – allowing our …See details»
Marinomed Biotech AG | LinkedIn
Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline and globally marketed therapeutics. The Company develops innovative …See details»
Marinomed Biotech AG Company Description - Stock Analysis
Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and …See details»
Life Sciences Directory: Marinomed Biotech AG
Marinomed Biotech AG is a biopharmaceutical company focused on inventing, developing, and partnering clinically meaningful therapies for patients suffering from serious viral infectious …See details»
Austria: Marinomed receives EUR 15m EIB financing
Feb 26, 2019 · The EIB is providing EUR 15m to Marinomed Biotech AG, a Vienna-based biopharmaceutical company developing innovative therapies for allergy, respiratory and eye …See details»
Marinomed Biotech AG Corporate Presentation
Oct 15, 2024 · 1 Publications available at: https://www.marinomed.com/en/news/scientific -publications/?virology marinomed Recent developments • Received MDR certificates for first …See details»
Solv4U :: Solv4U
Marinomed offers biopharmaceutical services tailored to suit your R&D projects as well as face your solubility challenges with your API. Meet our BD team at major industry events! Read here latest news and publications regarding our …See details»
Carragelose :: Carragelose
For 2024, the launch of an allergen-blocking nasal spray and mositurizing eye drops is planned. In addition, a Carragelose inhalation solution is in development. Carragelose forms a protective layer on mucosal surfaces that prevents …See details»
Marinomed Company Profile - Office Locations, Competitors
Sep 19, 2024 · See insights on Marinomed including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Marinomed - Company profile | ensun
Marinomed has developed a wide range of OTC products containing the polymer Carragelose®. Marinomed has the vision to transform the lives of people suffering from diseases with limited …See details»
Pipeline - Marinomed
Marinomed has a growing research pipeline of innovative products for two key therapeutic areas: Immunology and virology.See details»
Marinomed Biotech AG with Carragelose record sales in 2022
Apr 19, 2023 · About Marinomed Biotech AG: Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline and globally marketed therapeutics.See details»
Marinomed Biotechnologie GmbH | Insights
Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
News Details :: Marinomed
1 day ago · Marinomed to sell Carragelose business to Unither Pharmaceuticals, a leading contract development and manufacturing organization (CDMO) of medical devices and …See details»
Marinomed Biotech : Reports Financial Results for 1st Half 2021 …
Aug 25, 2021 · DGAP-News: Marinomed Biotech AG / Key word: Half Year Report Marinomed Biotech AG Reports Financial Results for 1st Half 2021 with significant revenue growth …See details»
News Details :: Marinomed
2 days ago · Korneuburg, Austria, November 26, 2024 - Marinomed Biotech AG (the “Company”) announces the signing of an agreement for the sale of its Carragelose business to French …See details»
Scientific Publications - Marinomed
Find here all scientific publications related to Marinomeds research.See details»